Cargando…
Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
BACKGROUND: An extensive crosstalk co-regulates the Hippo and Wnt pathway. Preclinical studies revealed that the Hippo transducers YAP/TAZ mediate a number of oncogenic functions in gastric cancer (GC). Moreover, comprehensive characterization of GC demonstrated that the Wnt pathway is targeted by o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800016/ https://www.ncbi.nlm.nih.gov/pubmed/29402328 http://dx.doi.org/10.1186/s12967-018-1385-y |
_version_ | 1783298120310849536 |
---|---|
author | Melucci, Elisa Casini, Beatrice Ronchetti, Livia Pizzuti, Laura Sperati, Francesca Pallocca, Matteo De Nicola, Francesca Goeman, Frauke Gallo, Enzo Amoreo, Carla Azzurra Sergi, Domenico Terrenato, Irene Vici, Patrizia Di Lauro, Luigi Diodoro, Maria Grazia Pescarmona, Edoardo Barba, Maddalena Mazzotta, Marco Mottolese, Marcella Fanciulli, Maurizio Ciliberto, Gennaro De Maria, Ruggero Buglioni, Simonetta Maugeri-Saccà, Marcello |
author_facet | Melucci, Elisa Casini, Beatrice Ronchetti, Livia Pizzuti, Laura Sperati, Francesca Pallocca, Matteo De Nicola, Francesca Goeman, Frauke Gallo, Enzo Amoreo, Carla Azzurra Sergi, Domenico Terrenato, Irene Vici, Patrizia Di Lauro, Luigi Diodoro, Maria Grazia Pescarmona, Edoardo Barba, Maddalena Mazzotta, Marco Mottolese, Marcella Fanciulli, Maurizio Ciliberto, Gennaro De Maria, Ruggero Buglioni, Simonetta Maugeri-Saccà, Marcello |
author_sort | Melucci, Elisa |
collection | PubMed |
description | BACKGROUND: An extensive crosstalk co-regulates the Hippo and Wnt pathway. Preclinical studies revealed that the Hippo transducers YAP/TAZ mediate a number of oncogenic functions in gastric cancer (GC). Moreover, comprehensive characterization of GC demonstrated that the Wnt pathway is targeted by oncogenic mutations. On this ground, we hypothesized that YAP/TAZ- and Wnt-related biomarkers may predict clinical outcomes in GC patients treated with chemotherapy. METHODS: In the present study, we included 86 patients with advanced GC treated with first-line chemotherapy in prospective phase II trials or in routine clinical practice. Tissue samples were immunostained to evaluate the expression of YAP/TAZ. Mutational status of key Wnt pathway genes (CTNNB1, APC and FBXW7) was assessed by targeted DNA next-generation sequencing (NGS). Survival curves were estimated and compared by the Kaplan–Meier product-limit method and the log-rank test, respectively. Variables potentially affecting progression-free survival (PFS) were verified in univariate Cox proportional hazard models. The final multivariate Cox models were obtained with variables testing significant at the univariate analysis, and by adjusting for all plausible predictors of the outcome of interest (PFS). RESULTS: We observed a significant association between TAZ expression and Wnt mutations (Chi-squared p = 0.008). Combined TAZ expression and Wnt mutations (TAZ(pos)/WNT(mut)) was more frequently observed in patients with the shortest progression-free survival (negative outliers) (Fisher p = 0.021). Uni-and multivariate Cox regression analyses revealed that patients whose tumors harbored the TAZ(pos)/WNT(mut) signature had an increased risk of disease progression (univariate Cox: HR 2.27, 95% CI 1.27–4.05, p = 0.006; multivariate Cox: HR 2.73, 95% CI 1.41–5.29, p = 0.003). Finally, the TAZ(pos)/WNT(mut) signature negatively impacted overall survival. CONCLUSIONS: Collectively, our findings indicate that the oncogenic YAP/TAZ–Wnt crosstalk may be active in GC, conferring chemoresistant traits that translate into adverse survival outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1385-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5800016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58000162018-02-13 Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy Melucci, Elisa Casini, Beatrice Ronchetti, Livia Pizzuti, Laura Sperati, Francesca Pallocca, Matteo De Nicola, Francesca Goeman, Frauke Gallo, Enzo Amoreo, Carla Azzurra Sergi, Domenico Terrenato, Irene Vici, Patrizia Di Lauro, Luigi Diodoro, Maria Grazia Pescarmona, Edoardo Barba, Maddalena Mazzotta, Marco Mottolese, Marcella Fanciulli, Maurizio Ciliberto, Gennaro De Maria, Ruggero Buglioni, Simonetta Maugeri-Saccà, Marcello J Transl Med Research BACKGROUND: An extensive crosstalk co-regulates the Hippo and Wnt pathway. Preclinical studies revealed that the Hippo transducers YAP/TAZ mediate a number of oncogenic functions in gastric cancer (GC). Moreover, comprehensive characterization of GC demonstrated that the Wnt pathway is targeted by oncogenic mutations. On this ground, we hypothesized that YAP/TAZ- and Wnt-related biomarkers may predict clinical outcomes in GC patients treated with chemotherapy. METHODS: In the present study, we included 86 patients with advanced GC treated with first-line chemotherapy in prospective phase II trials or in routine clinical practice. Tissue samples were immunostained to evaluate the expression of YAP/TAZ. Mutational status of key Wnt pathway genes (CTNNB1, APC and FBXW7) was assessed by targeted DNA next-generation sequencing (NGS). Survival curves were estimated and compared by the Kaplan–Meier product-limit method and the log-rank test, respectively. Variables potentially affecting progression-free survival (PFS) were verified in univariate Cox proportional hazard models. The final multivariate Cox models were obtained with variables testing significant at the univariate analysis, and by adjusting for all plausible predictors of the outcome of interest (PFS). RESULTS: We observed a significant association between TAZ expression and Wnt mutations (Chi-squared p = 0.008). Combined TAZ expression and Wnt mutations (TAZ(pos)/WNT(mut)) was more frequently observed in patients with the shortest progression-free survival (negative outliers) (Fisher p = 0.021). Uni-and multivariate Cox regression analyses revealed that patients whose tumors harbored the TAZ(pos)/WNT(mut) signature had an increased risk of disease progression (univariate Cox: HR 2.27, 95% CI 1.27–4.05, p = 0.006; multivariate Cox: HR 2.73, 95% CI 1.41–5.29, p = 0.003). Finally, the TAZ(pos)/WNT(mut) signature negatively impacted overall survival. CONCLUSIONS: Collectively, our findings indicate that the oncogenic YAP/TAZ–Wnt crosstalk may be active in GC, conferring chemoresistant traits that translate into adverse survival outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1385-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-05 /pmc/articles/PMC5800016/ /pubmed/29402328 http://dx.doi.org/10.1186/s12967-018-1385-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Melucci, Elisa Casini, Beatrice Ronchetti, Livia Pizzuti, Laura Sperati, Francesca Pallocca, Matteo De Nicola, Francesca Goeman, Frauke Gallo, Enzo Amoreo, Carla Azzurra Sergi, Domenico Terrenato, Irene Vici, Patrizia Di Lauro, Luigi Diodoro, Maria Grazia Pescarmona, Edoardo Barba, Maddalena Mazzotta, Marco Mottolese, Marcella Fanciulli, Maurizio Ciliberto, Gennaro De Maria, Ruggero Buglioni, Simonetta Maugeri-Saccà, Marcello Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title_full | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title_fullStr | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title_full_unstemmed | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title_short | Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
title_sort | expression of the hippo transducer taz in association with wnt pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800016/ https://www.ncbi.nlm.nih.gov/pubmed/29402328 http://dx.doi.org/10.1186/s12967-018-1385-y |
work_keys_str_mv | AT meluccielisa expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT casinibeatrice expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT ronchettilivia expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT pizzutilaura expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT speratifrancesca expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT palloccamatteo expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT denicolafrancesca expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT goemanfrauke expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT galloenzo expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT amoreocarlaazzurra expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT sergidomenico expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT terrenatoirene expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT vicipatrizia expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT dilauroluigi expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT diodoromariagrazia expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT pescarmonaedoardo expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT barbamaddalena expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT mazzottamarco expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT mottolesemarcella expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT fanciullimaurizio expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT cilibertogennaro expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT demariaruggero expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT buglionisimonetta expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy AT maugerisaccamarcello expressionofthehippotransducertazinassociationwithwntpathwaymutationsimpactssurvivaloutcomesinadvancedgastriccancerpatientstreatedwithfirstlinechemotherapy |